Comparative Pharmacology
Head-to-head clinical analysis: SYNALAR HP versus YUTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNALAR HP versus YUTIQ.
SYNALAR-HP vs YUTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
YUTIQ (fluocinolone acetonide intravitreal implant) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, suppression of arachidonic acid release, and downregulation of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This reduces inflammation and vascular permeability in the eye.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
0.18 mg fluocinolone acetonide intravitreal implant (single administration) releasing 0.2 mcg/day over 36 months.
None Documented
None Documented
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
Approximately 36 months (3 years) from the intravitreal implant; reflects sustained release from the non-biodegradable implant matrix.
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Primarily hepatic/biliary; fecal excretion is the major route. Renal excretion of fluocinolone acetonide and metabolites accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid